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Background/aim: Mucormycosis is a rare invasive fungal infection most commonly encountered in the immunocompromised host.
We analyzed 51 adult patients treated for mucormycosis between 2003 and 2013 and recorded at a tertiary university hospital in Turkey.
Materials and methods: We examined the following data for all patients: age, sex, predisposing disease, symptoms, treatment, surgical
procedure, concomitant infections, intensive care requirement, and outcomes.
Results: During the study period 51 cases of mucormycosis were documented; 54.9% of the patients were female. The mean age was
44.2 ± 18.2 years. Rhinocerebral presentation was reported in 94.1% of patients. Almost all patients (88.2%) had at least one risk factor.
The common predisposing factors were hematologic malignancies (52.9%), diabetes mellitus (25.5%), and solid malignancies (5.8%).
The most common initial symptoms were fever, cellulitis, and facial pain. The primary medication used was liposomal amphotericin B
or conventional amphotericin B. Surgery was performed in 94.1% of patients. Mortality was 52.9%.
Conclusion: Our study revealed that mucormycosis continues to be a mortal disease in about half of the cases. Our findings indicate
that treatment with L-AMB is associated with a favorable response. Also, in the case of facial pain, the low mortality rate may indicate
the importance of early diagnosis.
Key words: Facial pain, fever, liposomal amphotericin, mucormycosis

1. Introduction
Mucormycosis is a rare invasive fungal infection most
commonly encountered in immunocompromised hosts.
Risk factors for the development of mucormycosis include
poorly controlled diabetes or diabetic ketoacidosis,
prolonged neutropenia, renal disease, liver cirrhosis,
high dose steroids, and malignancies such as leukemia
and lymphoma. Mucormycosis may also affect
immunocompetent patients with trauma and burns, or
patients under deferoxamine treatment (1,2).
Aggressive surgery, combined with systemic antifungal
treatment, is the main applied treatment modality (3,4).
Despite these treatments, mortality and morbidity rates
are high. Early diagnosis, underlying disease, and form
of mucormycosis are determinative factors for prognosis
(2,5).
In recent years, mucormycosis appears to be increasing
worldwide (6,7). Thus, we aimed to analyze the local
epidemiology and outcome of mucormycosis in our center.
* Correspondence: skomur@gmail.com
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2. Materials and methods
The Çukurova University Hospital is a tertiary teaching
center with 1200 beds. From January 2003 to May 2013
a total of 51 cases of mucormycosis were recorded at
the Çukurova University Hospital. The diagnosis of
mucormycosis was confirmed histologically. Patients with
a histopathology report of aseptate or pauciseptate, broad,
thin-walled fungal hyphae branching at right angles were
reviewed.
The
demographic
characteristics,
underlying
conditions, site of infection, clinical signs and symptoms of
infection, radiological findings, treatments, and outcome
were extracted from the clinical records of patients.
2.1. Statistical analyses
Comparisons were made by Fisher’s exact and chi-square
tests as appropriate. Kaplan–Meier curves were analyzed by
the log-rank test. Results were represented as means ± SD,
median (min–max), and n (%). P < 0.05 was considered as
significant. Statistical analysis was performed using SPSS
v 20.0.
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3. Results
Over the 10-year period, 51 adult patients with
mucormycosis were identified. Twenty-eight (54.9%) of
them were female. The mean age was 44.2 ± 18.2 (17–
85) years. Almost all patients (88.2%) had at least one
underlying condition at the time of infection. Underlying
conditions are shown in Table 1. Six patients (11.8%) had
no predisposing factors.
Sinus involvement consisting of rhinocerebral, sinus,
and sino-orbital infections constituted the majority of
infections (94.1%). Orbital and cerebral involvement
was reported in 27.5% and 19.6%, respectively. Bone
destruction was detected in 17 (33.3%) patients, and 5
(9.8%) patients had abscesses. Pulmonary, thyroid, and
colon involvement was 2% each.
Twenty-four patients with hematological malignancies
(24/27) had the rhino-orbital form and the other three
patients had pulmonary, thyroid, or colon involvement.
Fourteen (27.5%) of these patients had neutropenia.
In all cases the diagnosis of mucormycosis was made
by histopathology.
The most common initial symptoms were fever
(70.6%), facial edema (62.7%), and facial pain (49%).
Unconsciousness (5.9%), ketoacidosis (5.9%), and
rhinorrhea (9.8%) were the other findings. Eight patients
(15.7%) had hard palate ulcerations on the nasal mucosa
in endoscopic examination.
All patients received medical treatment. The primary
medication used was liposomal amphotericin B (L-AMB)
(72.5%) or conventional amphotericin B (C-AMB)
(27.5%). Maintenance treatment with posaconazole was
Table 1. Underlying condition of patients.
Underlying condition

Number of patients (%)

Hematological malignancy

27 (52.9)

Neutropenia

14/27 (51.8)

Intensive care unit

16/27 (59.2)

Diabetes mellitus

2/27 (7.4)

Diabetes mellitus
Intensive care unit
Solid malignancy
Intensive care unit
Renal transplantation
Steroid use
Pregnancy
Intensive care unit

13 (25.5)

used in 11.8% of patients. Hypokalemia (64.7%) and
nephrotoxicity (45.1%) were common side effects.
Overall 94.1% of patients had surgery. Thirty-nine
(81.3%) of these patients had endoscopic sinus surgery,
7 (14.6%) had open surgery, and two patients had both
endoscopic sinus surgery and open surgery. Patients had
to be operated on several times due to recurrences. The
number of operations was between 1 and 6 (mean: 1.6 ±
1.1).
Twenty-seven patients (52.9%) were hospitalized
in the intensive care unit and 28 (54.9%) patients had
concomitant infection. These infections are listened in
Table 2.
Mortality was 52.9%. Sex, cerebral/orbital involvement,
presence of risk factors, diabetes, drug side effect, and type
of surgery were not associated with mortality. However,
concomitant infection, the absence of facial pain and fever
at the time of presentation, and treatment with C-AMB
were associated with increased mortality. The mortality of
patients followed in the intensive care unit was statistically
higher than that of the other patients (P < 0.005). In
patients with facial pain the mortality rate was significantly
lower than that in patients without facial pain (P < 0.005).
The response rate of patients treated with C-AMB was
21.4%, while the response rate was 56.8% in patients who
received L-AMB. In our patients, therapy with L-AMB
was associated with a favorable response and high survival
rates when compared with C-AMB (P < 0.05) (Figure).
4. Discussion
We analyzed 51 adult cases with mucormycosis over a
10-year period. There have been several reports from
Turkey, but to our knowledge our report is the largest case
series reported from a single hospital (8–10). In a recent
report, 151 zygomycosis cases from different centers were
evaluated by the pooled analysis method and 87.8% of the
cases were diagnosed as the rhino-orbito-cerebral form
(11). In most series rhinocerebral infection is the most
common clinical presentation (5,7,12). Similarly to these

Table 2. Concomitant infections.
Number of patients (%)

7/13 (53.8)
3 (5.8)

Pneumonia

20 (39.2)

3/3 (100)

Bacteremia

4 (7.8)

1 (1.9)

Urinary infection + pneumonia

1 (1.9)

1 (100)

Soft tissue infection

2 (3.9)

1 (1.9)

Pancreatitis

1 (1.9)

1/1 (100)

Total

28 (54.9)
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Figure. A comparison of survival times of patients treated with
C-AMB and those treated with L-AMB.

reports, almost all of our patients had the rhino-orbitocerebral form. Pulmonary zygomycosis is more common
in patients with hematological malignancies and bone
marrow transplantations than other populations (5,7,12).
In our hospital, bone marrow transplantation had not
been performed in those years; therefore, the distribution
of infection may be different from the literature.
In most studies, hematologic malignancy was reported
as the most common underlying disease. Ambrosioni et
al. reported that hematological malignancy was the most
common predisposing factor in a tertiary care hospital
and 75% of these patients had allogenic bone marrow
transplantation (7). In the study of Bitar et al. an increased
incidence in patients with hematological malignancies
was reported; however, Roden et al. reported that the
most common underlying condition was diabetes (2,6).
In our study the most prominent underlying diseases
were hematological malignancies and diabetes mellitus.
Solid malignancies, steroid usage, and pregnancy were
other predisposing factors. Six patients had no identified
predisposing factor. There have been several reports
of mucormycosis cases with no predisposing factors
(1,13,14).
The diagnosis of mucormycosis is challenging. Antigen
detection tests are not available. Therefore, tissue biopsy
for histopathology and culture is mandatory for diagnosis.
The culture also allows identification on the species level
and eventually antifungal susceptibility testing (15,16).
In a review of 929 zygomycosis cases, a positive culture
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result was obtained in 50% of the cases (2). In our center
culture was not feasible due to a number of reasons,
such as inappropriate sampling and storage of samples
until examined. Therefore, the diagnosis of our patients
was confirmed by histopathological and radiological
examination in addition to clinical findings.
Mucormycosis was reported primarily in males (65%)
by Roden et al. (2). In a case series report from Turkey,
52% of 151 patients were male and the mean age was 45.4
± 21.4 years (11). The mean age and sex distributions of
our patients were similar.
The management of mucormycosis should include
antifungal therapy, surgical debridement, and control
of underlying conditions. Amphotericin B has shown
excellent activity and L-AMB is more effective than the
C-AMB in murine models (17). The use of antifungal
therapy other than liposomal AmB was reported with
increased mortality in many studies. In the study of
Roden et al., the response rate of patients who had been
treated with C-AMB was 61%, while the response rate
of patients who had received L-AMB was 69% (2). In
our patients, therapy with L-AMB was associated with a
favorable response. Salvage treatment may be necessary
and posaconazole is strongly recommended (16). In a
review that consisted of 96 mucormycosis cases treated
with posaconazole, a complete response was reported in
64.6% of the cases, and overall mortality was 24% (18).
Our 6 patients received posaconazole as a maintenance
therapy following L-AMB, and only one of these patients
died.
Optimal duration of treatment has not been studied
previously (16). The mean treatment duration was 35.6
± 35 days in our patients. ESCMID and ECMM Joints
recommend continuing antifungal treatment until a
complete resolution as demonstrated on imaging (16).
Clinical trials documented higher survival rates with
a combined modality approach of surgical and medical
treatment (3,4,16). In a retrospective study, surgical
debridement of lung involvement was associated with a
decreased mortality from 62% to 11% (19). Most of our
patients had surgery. Vironneau et al. showed that surgery
is of major importance especially in rhino-orbito-cerebral
locations (20). Most of our patients had the rhino-orbitocerebral form.
Mortality rates varied in the different studies and
also according to different underlying conditions and
localization (1,2,7,21). Petrikkos et al. reported 54%
mortality and Lanternier et al. found 44% at day 90
and this differed significantly according to localization
(22,23,24). The overall mortality rate of our patients was
52.9%, which is similar to other reports. The mortality of
patients followed in the intensive care unit was statistically
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higher than that of the other patients. Intensive care
patients were followed with the expectation of worsening
cases. In our patients, therapy with L-AMB was associated
with a favorable response and improved survival rates
when compared with therapy with C-AMB. Our findings
were supported by Roden et al. and Rüping et al. (2,25). In
the patients with facial pain the lower mortality rate may
be due to early diagnosis.

In conclusion, our study revealed that mucormycosis
continues to be a mortal disease in about half of the
cases. Our findings indicate that treatment with L-AMB
is associated with a favorable response. Also, in the case
of facial pain the low mortality rate may indicate the
importance of early diagnosis. Despite the high mortality
rates, early and rapid medical treatment combined with
surgery seems to be promising for mucormycosis patients.
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